多年来糖尿病治疗的演变:从饥饿饮食到胰岛素、肠促胰岛素、sglt2抑制剂等

IF 1.8 4区 综合性期刊 Q2 MULTIDISCIPLINARY SCIENCES
Sunder Mudaliar
{"title":"多年来糖尿病治疗的演变:从饥饿饮食到胰岛素、肠促胰岛素、sglt2抑制剂等","authors":"Sunder Mudaliar","doi":"10.1007/s41745-023-00357-w","DOIUrl":null,"url":null,"abstract":"<div><p>Diabetes is an ancient disease and for centuries extreme diets and herbal remedies were used to treat diabetes symptoms. The discovery of insulin in 1921 transformed the landscape of diabetes treatment and was followed by the discovery of several new therapies which improved glycemia and increased patient life span. However, as patients with diabetes lived longer, they developed classic microvascular and macrovascular diabetes complications. In the 1990s, the DCCT and the UKPDS trials demonstrated that tight glucose control reduced the microvascular complications of diabetes, but had marginal effects on cardiovascular disease, the leading cause of death in patients with diabetes. In 2008, the FDA directed that all new diabetes medications demonstrate cardiovascular safety. From this recommendation emerged novel therapeutic classes, the GLP-1 receptor agonists and SGLT2-Inhibitors, which not only improve glycemia, but also provide robust cardio-renal protection. In parallel, developments in diabetes technology like continuous glucose monitoring systems, insulin pumps, telemedicine and precision medicine have advanced diabetes management. Remarkably, a century later, insulin remains a cornerstone of diabetes treatment. Also, diet and physical activity remain important components of any diabetes treatment. Today type 2 diabetes is preventable and long-term remission of diabetes is possible. Finally, progress continues in the field of islet transplantation, perhaps the ultimate frontier in diabetes management.\n</p></div>","PeriodicalId":675,"journal":{"name":"Journal of the Indian Institute of Science","volume":"103 1","pages":"123 - 133"},"PeriodicalIF":1.8000,"publicationDate":"2023-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s41745-023-00357-w.pdf","citationCount":"1","resultStr":"{\"title\":\"The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond\",\"authors\":\"Sunder Mudaliar\",\"doi\":\"10.1007/s41745-023-00357-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Diabetes is an ancient disease and for centuries extreme diets and herbal remedies were used to treat diabetes symptoms. The discovery of insulin in 1921 transformed the landscape of diabetes treatment and was followed by the discovery of several new therapies which improved glycemia and increased patient life span. However, as patients with diabetes lived longer, they developed classic microvascular and macrovascular diabetes complications. In the 1990s, the DCCT and the UKPDS trials demonstrated that tight glucose control reduced the microvascular complications of diabetes, but had marginal effects on cardiovascular disease, the leading cause of death in patients with diabetes. In 2008, the FDA directed that all new diabetes medications demonstrate cardiovascular safety. From this recommendation emerged novel therapeutic classes, the GLP-1 receptor agonists and SGLT2-Inhibitors, which not only improve glycemia, but also provide robust cardio-renal protection. In parallel, developments in diabetes technology like continuous glucose monitoring systems, insulin pumps, telemedicine and precision medicine have advanced diabetes management. Remarkably, a century later, insulin remains a cornerstone of diabetes treatment. Also, diet and physical activity remain important components of any diabetes treatment. Today type 2 diabetes is preventable and long-term remission of diabetes is possible. Finally, progress continues in the field of islet transplantation, perhaps the ultimate frontier in diabetes management.\\n</p></div>\",\"PeriodicalId\":675,\"journal\":{\"name\":\"Journal of the Indian Institute of Science\",\"volume\":\"103 1\",\"pages\":\"123 - 133\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2023-02-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s41745-023-00357-w.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Indian Institute of Science\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s41745-023-00357-w\",\"RegionNum\":4,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Indian Institute of Science","FirstCategoryId":"103","ListUrlMain":"https://link.springer.com/article/10.1007/s41745-023-00357-w","RegionNum":4,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 1

摘要

糖尿病是一种古老的疾病,几个世纪以来,人们一直使用极端饮食和草药来治疗糖尿病症状。1921年胰岛素的发现改变了糖尿病治疗的格局,随后又发现了几种新的治疗方法,这些方法改善了血糖水平,延长了患者的寿命。然而,随着糖尿病患者寿命的延长,他们出现了典型的微血管和大血管糖尿病并发症。在20世纪90年代,DCCT和UKPDS试验表明,严格的血糖控制减少了糖尿病的微血管并发症,但对心血管疾病的影响微乎其微,心血管疾病是糖尿病患者死亡的主要原因。2008年,FDA指示所有新的糖尿病药物必须证明心血管安全。从这一建议中出现了新的治疗类别,GLP-1受体激动剂和sglt2抑制剂,它们不仅可以改善血糖,还可以提供强大的心肾保护。与此同时,连续血糖监测系统、胰岛素泵、远程医疗和精准医疗等糖尿病技术的发展也促进了糖尿病的管理。值得注意的是,一个世纪之后,胰岛素仍然是糖尿病治疗的基石。此外,饮食和体育活动仍然是任何糖尿病治疗的重要组成部分。今天,2型糖尿病是可以预防的,糖尿病的长期缓解是可能的。最后,胰岛移植领域的进展仍在继续,这可能是糖尿病治疗的终极前沿。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond

The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond

Diabetes is an ancient disease and for centuries extreme diets and herbal remedies were used to treat diabetes symptoms. The discovery of insulin in 1921 transformed the landscape of diabetes treatment and was followed by the discovery of several new therapies which improved glycemia and increased patient life span. However, as patients with diabetes lived longer, they developed classic microvascular and macrovascular diabetes complications. In the 1990s, the DCCT and the UKPDS trials demonstrated that tight glucose control reduced the microvascular complications of diabetes, but had marginal effects on cardiovascular disease, the leading cause of death in patients with diabetes. In 2008, the FDA directed that all new diabetes medications demonstrate cardiovascular safety. From this recommendation emerged novel therapeutic classes, the GLP-1 receptor agonists and SGLT2-Inhibitors, which not only improve glycemia, but also provide robust cardio-renal protection. In parallel, developments in diabetes technology like continuous glucose monitoring systems, insulin pumps, telemedicine and precision medicine have advanced diabetes management. Remarkably, a century later, insulin remains a cornerstone of diabetes treatment. Also, diet and physical activity remain important components of any diabetes treatment. Today type 2 diabetes is preventable and long-term remission of diabetes is possible. Finally, progress continues in the field of islet transplantation, perhaps the ultimate frontier in diabetes management.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of the Indian Institute of Science
Journal of the Indian Institute of Science MULTIDISCIPLINARY SCIENCES-
CiteScore
4.30
自引率
0.00%
发文量
75
期刊介绍: Started in 1914 as the second scientific journal to be published from India, the Journal of the Indian Institute of Science became a multidisciplinary reviews journal covering all disciplines of science, engineering and technology in 2007. Since then each issue is devoted to a specific topic of contemporary research interest and guest-edited by eminent researchers. Authors selected by the Guest Editor(s) and/or the Editorial Board are invited to submit their review articles; each issue is expected to serve as a state-of-the-art review of a topic from multiple viewpoints.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信